REGINfo: Orion - Pharmacie - Financial information

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DISCOUNT
- ELBIT SYSTEMS
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- MAZOR ROBOTICS
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- POALIM
- SHUFERSAL
- SODASTREAM
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

OMXH 25 NEWS

FEEDS

My Google

Microsoft Live

My Yahoo

COMPANY SEARCH RESULT

$Orion: Click to view the issuer\'s details$

Last update : 03/04/2012 >View issuer details

2019.01.09 | 11:40 | Permanent Information Releases / Appointments

puce Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2019 AGM of Orion Corporation - HTML (w)

2019.01.04 | 08:00 | Permanent Information Releases / General Company News

puce Orion Corporation and Fifth Corner Inc join forces to research solutions for improving the quality of life of prostate cancer patients - HTML (w)

2018.12.04 | 14:00 | Permanent Information Releases / General Company News

puce Orion acquires sales and distribution rights for certain European Countries for Parkinson's disease drug Stalevo - HTML (w)

2018.10.24 | 11:30 | Permanent Information Releases / General Company News

puce Orion and Amgen to collaborate on the commercialisation of AMGEVITA® (biosimilar adalimumab) in Finland - HTML (w)

2018.10.24 | 11:00 | Periodic information / 3rd Quarter Information

puce Orion Group Interim Report January-September 2018 - HTML (w)

2018.10.24 | 07:30 | Permanent Information Releases / General Company News

puce Orion and Bayer have completed the phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer - The primary endpoint was met - HTML (w)

2018.10.24 | Periodic information / 3rd Quarter Information

puce Orion : Interim Report January–September 2018 - PDF (634Kb)

2018.10.10 | 12:00 | Permanent Information Releases / Notification of availability

puce Publishing of Orion Corporation's Interim Report for January-September 2018 on 24 October 2018 - HTML (w)

2018.09.19 | 10:45 | Periodic information / Internal Control & Corporate Governance

puce Changes in responsibility areas of the Orion Group Executive Management Board - HTML (w)

2018.09.17 | 11:00 | Permanent Information Releases / General Company News

puce Creation of novel medicines and better patient care for the future in an ecosystem - HTML (w)

2018.09.10 | 09:00 | Permanent Information Releases / Appointments

puce Johanna Ivaska has been appointed Head & Vice President of Oncology Research in Orion Corporation - HTML (w)

2018.07.18 | 11:00 | Periodic information / Half-Year Financial Report

puce Orion Group Half-Year Financial Report January-June 2018 - HTML (w)

2018.07.18 | 10:00 | Permanent Information Releases / Notification of availability

puce Orion Corporation's financial reporting and Annual General Meeting in 2019 - HTML (w)

2018.07.18 | Periodic information / Half-Year Financial Report

puce Orion : HALF-YEAR FINANCIAL REPORT JANUARY–JUNE 2018 - PDF (929Kb)

2018.07.06 | 10:00 | Permanent Information Releases / General Company News

puce Orion has started a Phase III trial to develop a drug for ALS - The patient recruitment has begun - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 166